Roivant Sciences Announces Investor Conference for Brepocitinib in Dermatomyositis Treatment
ByAinvest
Tuesday, Jun 10, 2025 8:28 pm ET1min read
ROIV--
Roivant Sciences (Nasdaq: ROIV) and Priovant Therapeutics will host a live investor video conference on Tuesday, June 17, 2025, at 1:00 PM ET to discuss brepocitinib, a treatment for dermatomyositis (DM). The conference aims to highlight the potential impact of brepocitinib on patient outcomes, but success is contingent on ongoing clinical trial results.
Brepocitinib is a dual selective inhibitor of TYK2 and JAK1, designed to suppress key cytokines linked to autoimmunity. It has shown positive results in seven Phase 2 studies and is currently in Phase 3 trials for DM. The drug is administered as a once-daily oral therapy and has been dosed in over 1,400 subjects [1].
The video conference will provide an opportunity for investors to learn more about brepocitinib's clinical and therapeutic potential, as well as its commercialization prospects. The event will feature presentations and discussions from Roivant and Priovant executives, who will share their insights and expectations regarding the drug's development and future market opportunities.
The conference will be accessible via a registration link provided on Roivant's investor website [2]. An archived webcast will be available after the live event.
References:
[1] https://investor.roivant.com/news-releases/news-release-details/roivant-and-priovant-host-investor-video-conference-100-pm-et
[2] https://www.globenewswire.com/news-release/2025/06/09/3096179/0/en/Roivant-and-Priovant-to-Host-Investor-Video-Conference-at-1-00-PM-ET-on-Tuesday-June-17-on-Brepocitinib-and-the-Unmet-Medical-Need-in-Dermatomyositis.html
Roivant Sciences and Priovant Therapeutics will host a live investor video conference on June 17, 2025, to discuss brepocitinib, a treatment for dermatomyositis. Brepocitinib, a dual selective inhibitor of TYK2 and JAK1, has shown positive results in seven Phase 2 studies and is currently in Phase 3 trials. The conference aims to highlight its potential impact on patient outcomes, but success is contingent on ongoing clinical trial outcomes.
June 11, 2025Roivant Sciences (Nasdaq: ROIV) and Priovant Therapeutics will host a live investor video conference on Tuesday, June 17, 2025, at 1:00 PM ET to discuss brepocitinib, a treatment for dermatomyositis (DM). The conference aims to highlight the potential impact of brepocitinib on patient outcomes, but success is contingent on ongoing clinical trial results.
Brepocitinib is a dual selective inhibitor of TYK2 and JAK1, designed to suppress key cytokines linked to autoimmunity. It has shown positive results in seven Phase 2 studies and is currently in Phase 3 trials for DM. The drug is administered as a once-daily oral therapy and has been dosed in over 1,400 subjects [1].
The video conference will provide an opportunity for investors to learn more about brepocitinib's clinical and therapeutic potential, as well as its commercialization prospects. The event will feature presentations and discussions from Roivant and Priovant executives, who will share their insights and expectations regarding the drug's development and future market opportunities.
The conference will be accessible via a registration link provided on Roivant's investor website [2]. An archived webcast will be available after the live event.
References:
[1] https://investor.roivant.com/news-releases/news-release-details/roivant-and-priovant-host-investor-video-conference-100-pm-et
[2] https://www.globenewswire.com/news-release/2025/06/09/3096179/0/en/Roivant-and-Priovant-to-Host-Investor-Video-Conference-at-1-00-PM-ET-on-Tuesday-June-17-on-Brepocitinib-and-the-Unmet-Medical-Need-in-Dermatomyositis.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet